PPMS
MCID: PRM108
MIFTS: 46

Primary Progressive Multiple Sclerosis (PPMS) malady

Categories: Genetic diseases (common), Neuronal diseases

Aliases & Classifications for Primary Progressive Multiple Sclerosis

About this section

Aliases & Descriptions for Primary Progressive Multiple Sclerosis:

Name: Primary Progressive Multiple Sclerosis 11 50 13
Multiple Sclerosis, Primary Progressive 68
 
Primary-Progressive Ms 11
Ppms 11

Classifications:



External Ids:

Disease Ontology11 DOID:0050784
SNOMED-CT62 428700003
MeSH39 D020528

Summaries for Primary Progressive Multiple Sclerosis

About this section
Disease Ontology:11 A multiple sclerosis that is characterized by steady worsening of neurologic functioning, without any distinct relapses or periods of remission. The rate of progression may vary over time, with occasional plateaus or temporary improvements, but the progression is continuous.

MalaCards based summary: Primary Progressive Multiple Sclerosis, also known as multiple sclerosis, primary progressive, is related to mental retardation, x-linked, syndromic 13 and jamaican vomiting sickness. An important gene associated with Primary Progressive Multiple Sclerosis is IFNB1 (Interferon Beta 1), and among its related pathways are EBV LMP1 signaling and Glial Cell Differentiation. Affiliated tissues include brain, spinal cord and lymph node, and related mouse phenotypes are muscle and neoplasm.

Related Diseases for Primary Progressive Multiple Sclerosis

About this section

Diseases in the Primary Progressive Multiple Sclerosis family:

Multiple Sclerosis 4 Multiple Sclerosis 3
Multiple Sclerosis 2 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis

Diseases related to Primary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 107)
idRelated DiseaseScoreTop Affiliating Genes
1mental retardation, x-linked, syndromic 1311.7
2jamaican vomiting sickness11.0
3pyridoxal 5'-phosphate-dependent epilepsy10.3IL10, TNF
4tubular renal disease-cardiomyopathy syndrome10.3IL10, TNF
5lagophthalmos10.3IL10, TNF
6multiple vertebral anomalies unusual facies10.3IL10, TNF
7conidiobolomycosis10.2IL10, TNF
8parovarian cyst10.2IFNB1, TNF
9chordoid meningioma10.2IL10, MMP9, TNF
10burns10.2IL10, MMP9, TNF
11infancy electroclinical syndrome10.2IL10, MMP9, TNF
12neurotic disorder10.2ICAM1, IL10, TNF
13conduct disorder10.2ICAM1, IL10, TNF
14microcephaly10.2ICAM1, IL10, TNF
15acquired polycythemia10.2ICAM1, IL10, TNF
16tuberculosis10.2IFNB1, IL10, TNF
17neonatal hypoxic and ischemic brain injury10.2IL10, MMP9
18balkan nephropathy10.2ICAM1, IL10, TNF
19xanthogranulomatous cholecystitis10.2ICAM1, IL10, TNF
20amelogenesis imperfecta10.2ICAM1, IL10, TNF
21pyelonephritis10.2ICAM1, IL10, TNF
22benign eccrine breast spiradenoma10.2ICAM1, IL10, TNF
23parasitic protozoa infectious disease10.2ICAM1, IL10, TNF
24hyperuricemia, pulmonary hypertension, renal failure, and alkalosis10.2IL10, MMP9, TNF
25nonspecific interstitial pneumonia10.2ICAM1, IL10, TNF
26geniculate ganglionitis10.2ICAM1, IL10, TNF
27pulmonary eosinophilia10.2IL10, MMP9, TNF
28sclerosing adenosis of breast10.2ICAM1, IL10, TNF
29endosalpingiosis10.2IL10, TNF
30developmental coordination disorder10.2CSF1R, MMP9
31nervous system cancer10.2IL10, MMP9, TNF
32gastric dilatation10.2IL10, MBP, TNF
33esophageal candidiasis10.2ICAM1, IL10, TNF
34severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive10.1IL10, TNF
35intratubular embryonal carcinoma10.1IL10, MMP9, TNF
36non-gestational choriocarcinoma10.1IFNB1, IL10, MBP
37cervical adenoid basal carcinoma10.1IL10, MBP, MOG
38status epilepticus10.1MBP, MOG, TNF
39neonatal stroke10.1IL10, MBP, TNF
40right ventricle hypoplasia10.1ICAM1, TNF, VCAM1
41optic nerve hypoplasia10.1ICAM1, IL10, MMP9, TNF
42peripheral artery disease10.1IL10, TNF, VCAM1
43acute chest syndrome10.1ICAM1, IL10, MMP9, TNF
44alopecia-intellectual disability syndrome10.1MBP, MOG, PLP1
45root caries10.1
46hypopyon ulcer10.1ICAM1, VCAM1
47epidermolysis bullosa simplex, sutosomal recessive 210.1ICAM1, MMP9, VCAM1
48asbestosis10.1IL10, TNF, VCAM1
49macrodactyly of the foot10.1ICAM1, VCAM1
50respiratory system disease10.1IL10, TNF, VCAM1

Graphical network of the top 20 diseases related to Primary Progressive Multiple Sclerosis:



Diseases related to primary progressive multiple sclerosis

Symptoms & Phenotypes for Primary Progressive Multiple Sclerosis

About this section

MGI Mouse Phenotypes related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

41 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053698.9ICAM1, IL10, MMP9, MOG, PLP1, TNF
2MP:00020068.8ICAM1, IFNB1, IL10, IL7R, MMP9, TNF
3MP:00030128.7CSF1R, IFNB1, IL10, OMG, TNF, VCAM1
4MP:00028738.6CSF1R, IFNB1, IL10, IL7R, MBP, OMG
5MP:00053898.2CSF1R, IL10, MBP, MMP9, PLP1, TNF
6MP:00036318.0CSF1R, ICAM1, IFNB1, IL10, MBP, MMP9
7MP:00053917.8ICAM1, IL10, MBP, MMP9, MOG, PLP1
8MP:00053787.5CSF1R, ICAM1, IL10, MBP, MMP9, MOG
9MP:00053847.1CSF1R, ICAM1, IL10, IL7R, MBP, MMP9
10MP:00053976.8CSF1R, ICAM1, IFNB1, IL10, IL7R, MBP
11MP:00053876.8CSF1R, ICAM1, IFNB1, IL10, IL7R, MBP
12MP:00053766.5CSF1R, ICAM1, IFNB1, IL10, MBP, MMP9

Drugs & Therapeutics for Primary Progressive Multiple Sclerosis

About this section

Drugs for Primary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 268)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Mycophenolate mofetilapproved, investigationalPhase 4952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
2
Miconazoleapproved, investigational, vet_approvedPhase 4370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
3
Mycophenolic acidapprovedPhase 495224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
4
Procaineapproved, investigational, vet_approvedPhase 44959-46-14914
Synonyms:
.beta.-(Diethylamino)ethyl p-aminobenzoate
.beta.-Diethylaminoethyl 4-aminobenzoate
2-(Diethylamino)ethyl 4-aminobenzoate
2-(Diethylamino)ethyl p-aminobenzoate
2-(Diethylamino)ethyl-4-aminobenzoate
2-Diethylaminoethyl 4-aminobenzoate
2-Diethylaminoethyl p-aminobenzoate
2-Diethylaminoethylester kyseliny p-aminobenzoove
2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]
4-14-00-01138 (Beilstein Handbook Reference)
4-Aminobenzoesaeure-beta-diethylaminoethylester
4-Aminobenzoic acid 2-(diethylamino) ethyl ester
4-Aminobenzoic acid diethylaminoethyl ester
4-aminobenzoic acid 2-diethylaminoethyl ester
59-46-1
91484-72-9
AB00053531
AC1L1J8C
AC1Q2ZE2
AKOS000115407
Allocaine
Anticort
Anticort (TM)
Anuject
BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE
BPBio1_000179
BRD-K24616672-003-05-2
BRN 0913480
BSPBio_000161
BSPBio_002231
Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester
Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester
C07375
CAS-51-05-8
CHEBI:8430
CHEMBL569
CID4914
D08422
DB00721
Diethylaminoethyl p-aminobenzoate
DivK1c_000120
Duracaine
EINECS 200-426-9
Factor H3
Gerokit
Gerovital
Gerovital H-3
HSDB 3388
I06-1439
IDI1_000120
InChI=1/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H
Jenacain
Jenacaine
KBio1_000120
KBio2_001318
KBio2_003886
KBio2_006454
KBio3_001731
 
KBioGR_000975
KBioSS_001318
LS-35778
Lopac-P-9879
Lopac0_000966
MolPort-000-889-177
NCGC00015864-01
NCGC00015864-02
NCGC00015864-04
NCGC00162298-01
NINDS_000120
NSC 169497
NSC169497
Nissocaine
Norocaine
Novocain
Novocaine
Prestwick0_000041
Prestwick1_000041
Prestwick2_000041
Prestwick3_000041
Procain
Procaina
Procaina [INN-Spanish]
Procaine (INN)
Procaine HCl
Procaine [INN:BAN]
Procaine, base
Procainum
Procainum [INN-Latin]
SP-01A
SP01
SP01A
SPBio_001331
SPBio_002082
STK177303
STOCK2S-12721
Scurocaine
Solution of novocain
Solution of novocain (TN)
Spectrum2_001296
Spectrum3_000556
Spectrum4_000488
Spectrum5_001186
Spectrum_000838
Spinocaine
Stoff H3
UNII-4Z8Y51M438
Vitamin H3
WLN: ZR DVO2N2&2
beta-(Diethylamino)ethyl 4-aminobenzoate
beta-(Diethylamino)ethyl p-aminobenzoate
beta-Diethylaminoethyl 4-aminobenzoate
p-Aminobenzoic acid 2-diethylaminoethyl ester
p-Aminobenzoyldiethylaminoethanol
p-Aminobenzyoyldiethylaminoethanol
procaine
β-(diethylamino)ethyl 4-aminobenzoate
β-(diethylamino)ethyl p-aminobenzoate
5
Tacrolimusapproved, investigationalPhase 4, Phase 21102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
6
Sirolimusapproved, investigationalPhase 4194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
7
Interferon beta-1bapprovedPhase 4, Phase 3, Phase 284145155-23-3
Synonyms:
Betaseron
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
8
EverolimusapprovedPhase 41940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
9
4-AminopyridineapprovedPhase 4, Phase 369504-24-51727
Synonyms:
.gamma.-Aminopyridine
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 AP
4 Aminopyridine
4 Aminopyridine Sustained Release
4-AP
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-Pyridinamine
4-Pyridylamine
4-aminopyridine
5-22-09-00106 (Beilstein Handbook Reference)
504-24-5
A 0152
A0414
A78403_ALDRICH
AB1004971
AC-907/25014071
AC1L1C3R
AC1Q52BM
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
BRN 0105782
BSPBio_001562
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
C13728
C5H6N2
CHEBI:34385
CHEMBL284348
CID1727
Caswell No. 038
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
FT-0083754
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine SR
Fampridine [USAN:INN]
Fampridine-PR
Fampridine-SR
Fampridinum
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
KBio1_000572
 
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
LS-130202
Lopac-A-0152
Lopac0_000032
MLS000069400
Mi-W-3
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
NINDS_000572
NSC 15041
NSC15041
Neurelan
Neurelan (TN)
P-Aminopyridine
PYRIDINE,4-AMINO
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
SPECTRUM1501130
STK298717
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
Spectrum_000155
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 10-3
VMI 103
VMI-10-3
VMI-103
VMI103
WLN: T6NJ DZ
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
gamma-Aminopyridine
nchem.892-comp4
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
pyridin-4-amine
pyridin-4-ylamine
10
DopamineapprovedPhase 4, Phase 2, Phase 1383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
11
Prednisoloneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
12
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
13
Memantineapproved, investigationalPhase 4, Phase 218119982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
14
Gabapentinapproved, investigationalPhase 4, Phase 230360142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin
15
Dimethyl fumarateapproved, investigationalPhase 4, Phase 3, Phase 285624-49-7637568, 5271565
Synonyms:
(E)-CH3OC(O)CH=CHC(O)OCH3
(e)-But-2-enedioic acid dimethyl ester
1,2-Bis(methoxycarbonyl)-trans-Ethylene
1,2-Bis(methoxycarbonyl)-trans-ethylene
2-Butenedioic acid (2E)-, 1,4-dimethyl ester
2-Butenedioic acid (2E)-, dimethyl ester
2-Butenedioic acid (E)-, dimethyl ester
2-Butenedioic acid, dimethyl ester
Allomaleic acid dimethyl ester
BG 12 compound
BG-12
Boletic acid dimethyl ester
But-2-enedioic acid, dimethyl ester
Dimethyl (2E)-2-butenedioate
Dimethyl (2E)-but-2-enedioate
Dimethyl (E)-but-2-enedioate
Dimethyl but-2-enedioate
Dimethyl ester(2E)-2-Butenedioic acid
 
Dimethyl ester(E)-2-Butenedioic acid
Dimethyl fumarate
Dimethyl fumarate (usan)
Dimethyl trans-ethylenedicarboxylate
Dimethylester kyseliny fumarove
Dimethylfumarate
Fumaderm
Fumaric acid dimethyl ester
Fumaric acid, dimethyl ester
Fumaric acid, dimethyl ester (8CI)
Maleic acid, dimethyl ester
Methyl fumarate
Tecfidera
Trans-butenedioic acid dimethyl ester
dimethyl (E) butenedioate
trans-1, 2-Ethylenedicarboxylic acid dimethyl ester
trans-1,2-Ethylenedicarboxylic Acid dimethyl ester
trans-1,2-Ethylenedicarboxylic acid dimethyl ester
trans-Butenedioic acid dimethyl ester
16
Interferon beta-1aapproved, investigationalPhase 4, Phase 3200145258-61-36438354
Synonyms:
145258-61-3
Avonex
Avonex (TN)
Belerofon
D04554
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
Interferon beta-1a
Interferon beta-1a (USAN)
Interferon beta-1a (genetical recombination)
Interferon beta-1a (genetical recombination) (JAN)
17
Natalizumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1102189261-10-7
Synonyms:
189261-10-7
Anti-VLA4
Anti-alpha4 integrin
 
D06886
Natalizumab
Natalizumab (INN)
Tysabri
Tysabri (TN)
18
Prednisoneapproved, vet_approvedPhase 4139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
19Antifungal AgentsPhase 43696
20Anti-Infective AgentsPhase 4, Phase 3, Phase 1, Phase 222062
21Dopamine AgentsPhase 4, Phase 2, Phase 13836
22Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 118340
23Antibiotics, AntitubercularPhase 47180
24Anti-Bacterial AgentsPhase 411226
25Potassium Channel BlockersPhase 4, Phase 3180
26Calcineurin InhibitorsPhase 4, Phase 21622
27Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 1, Phase 210729
28Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 223689
29AnalgesicsPhase 4, Phase 1, Phase 211733
30Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113086
31Interferon-betaPhase 4, Phase 3, Phase 2, Phase 1284
32interferonsPhase 4, Phase 3, Phase 2, Phase 12175
33Antiviral AgentsPhase 4, Phase 3, Phase 1, Phase 29967
34Pharmaceutical SolutionsPhase 4, Phase 2, Phase 18192
35Adjuvants, ImmunologicPhase 4, Phase 3, Phase 22554
36Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113168
37HormonesPhase 4, Phase 3, Phase 2, Phase 114415
38Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15806
39glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 15103
40Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113180
41Methylprednisolone acetatePhase 4, Phase 3, Phase 2, Phase 11193
42Protective AgentsPhase 4, Phase 2, Phase 3, Phase 17443
43Neuroprotective AgentsPhase 4, Phase 2, Phase 3, Phase 11716
44Prednisolone hemisuccinatePhase 4, Phase 3, Phase 2, Phase 11193
45Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
46Methylprednisolone HemisuccinatePhase 4, Phase 3, Phase 2, Phase 11193
47Prednisolone phosphatePhase 4, Phase 3, Phase 2, Phase 11193
48Prednisolone acetatePhase 4, Phase 3, Phase 2, Phase 11193
49Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 110150
50AnticonvulsantsPhase 4, Phase 3, Phase 22695

Interventional clinical trials:

(show top 50)    (show all 199)
idNameStatusNCT IDPhase
1Resistance Training and Amino Pyridine in Multiple SclerosisUnknown statusNCT02143167Phase 4
2Kidney Biopsy Controlled Trial of Calcineurin Inhibitor WithdrawalUnknown statusNCT00896012Phase 4
3Pharmacokinetics of DMF and the Effects of DMF on Exploratory BiomarkersCompletedNCT02683863Phase 4
4Open-Label Safety Extension Study of AvonexCompletedNCT00915460Phase 4
5Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MSCompletedNCT00463710Phase 4
6Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple SclerosisCompletedNCT01795872Phase 4
7Treatment of Pendular Nystagmus in OPTCompletedNCT02466191Phase 4
8Methylprednisolone During the Switch Between Natalizumab and FingolimodRecruitingNCT02769689Phase 4
9Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)RecruitingNCT02739542Phase 4
10A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple SclerosisActive, not recruitingNCT02208050Phase 4
11Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive PatientsActive, not recruitingNCT03092544Phase 4
12Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to TeriflunomideActive, not recruitingNCT01970410Phase 4
13Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple SclerosisTerminatedNCT01411514Phase 4
14Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT01701856Phase 4
15The Efficacy of EMDR in Patients With PTSD in Multiple SclerosisUnknown statusNCT01743664Phase 3
16FTY720 in Patients With Primary Progressive Multiple SclerosisCompletedNCT00731692Phase 3
17A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple SclerosisCompletedNCT00087529Phase 2, Phase 3
18Neurophysiological Study of Sativex in Multiple Sclerosis (MS) SpasticityCompletedNCT01538225Phase 3
19Sunphenon in Progressive Forms of Multiple SclerosisCompletedNCT00799890Phase 2, Phase 3
20A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple SclerosisCompletedNCT01917019Phase 3
21Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple SclerosisCompletedNCT00241254Phase 3
22Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)CompletedNCT01188811Phase 2, Phase 3
23Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple SclerosisCompletedNCT00134563Phase 3
24Expiratory Muscle Training for Persons With Neurodegenerative DiseaseCompletedNCT00856518Phase 2, Phase 3
25Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-ApproachCompletedNCT02008721Phase 3
26Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)RecruitingNCT02688985Phase 3
27A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple SclerosisRecruitingNCT01433497Phase 2, Phase 3
28Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)RecruitingNCT02936037Phase 3
29A Task-oriented Circuit Training in Multiple SclerosisRecruitingNCT02421744Phase 3
30A Study of Ocrelizumab in Participants With Primary Progressive Multiple SclerosisActive, not recruitingNCT01194570Phase 3
31Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple SclerosisActive, not recruitingNCT02220244Phase 3
32Effect of MD1003 in Spinal Progressive Multiple SclerosisActive, not recruitingNCT02220933Phase 3
33Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized StudyActive, not recruitingNCT00273364Phase 3
34Effects of Acthar on Recovery From Cognitive Relapses in MSEnrolling by invitationNCT02290444Phase 3
35A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple SclerosisNot yet recruitingNCT02057159Phase 2, Phase 3
36Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated SyndromeNot yet recruitingNCT03122652Phase 3
37Hydroxyurea in Primary Progressive Multiple SclerosisTerminatedNCT01103583Phase 2, Phase 3
38A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisTerminatedNCT01416181Phase 3
39BG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisTerminatedNCT02430532Phase 3
40Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple SclerosisTerminatedNCT00468611Phase 3
41Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)TerminatedNCT00688948Phase 2, Phase 3
42Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)TerminatedNCT00211224Phase 3
43Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MSUnknown statusNCT02273635Phase 1, Phase 2
44The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple SclerosisUnknown statusNCT01144117Phase 2
45AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple SclerosisUnknown statusNCT01228396Phase 2
46Mesenchymal Stem Cells for the Treatment of MSUnknown statusNCT00781872Phase 1, Phase 2
47Combination Therapy of Betaseron-Prograf in Multiple SclerosisUnknown statusNCT00298662Phase 2
48Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum DisordersUnknown statusNCT02249676Phase 2
49Use of Cannabinoids in Patients With Multiple SclerosisUnknown statusNCT00202423Phase 2
50Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral SclerosisUnknown statusNCT01569958Phase 2

Search NIH Clinical Center for Primary Progressive Multiple Sclerosis

Genetic Tests for Primary Progressive Multiple Sclerosis

About this section

Anatomical Context for Primary Progressive Multiple Sclerosis

About this section

MalaCards organs/tissues related to Primary Progressive Multiple Sclerosis:

36
Brain, Spinal cord, Lymph node

Publications for Primary Progressive Multiple Sclerosis

About this section

Articles related to Primary Progressive Multiple Sclerosis:

(show top 50)    (show all 69)
idTitleAuthorsYear
1
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. (28002688)
2017
2
CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis. (27314966)
2016
3
Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis. (27778334)
2016
4
A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. (27072687)
2016
5
Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study. (26785711)
2016
6
Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. (26599831)
2016
7
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. (27813441)
2016
8
Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. (26706657)
2016
9
Primary progressive multiple sclerosis--why we are failing. (26827076)
2016
10
Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? (26993116)
2016
11
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal. (27159986)
2016
12
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. (26827074)
2016
13
Multimodal neurophysiological evaluation of primary progressive multiple sclerosis - An increasingly valid biomarker, with limits. (26590670)
2015
14
Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis. (26457955)
2015
15
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. (26393519)
2015
16
Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. (25583839)
2015
17
Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis. (26485710)
2015
18
Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study. (26246109)
2015
19
Melatonin treatment improves primary progressive multiple sclerosis: a case report. (25546814)
2015
20
Paroxetine-Related Adult-Onset Tic Disorder: A Presentation of Primary Progressive Multiple Sclerosis. (26222974)
2015
21
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. (25468777)
2015
22
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? (26263977)
2015
23
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. (25863355)
2015
24
Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. (25903918)
2015
25
Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. (25802867)
2015
26
PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. (25994655)
2015
27
Retraction notice: Language abilities of patients with primary progressive multiple sclerosis: A preliminary group and case investigation. (24766406)
2014
28
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. (24651401)
2014
29
Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. (25311247)
2014
30
Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. (24794503)
2014
31
Genetics of primary progressive multiple sclerosis. (24507520)
2014
32
Modelling the natural history of primary progressive multiple sclerosis. (24828900)
2014
33
Epstein-barr virus in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis. (24918642)
2014
34
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. (24099844)
2014
35
Adult-onset vanishing white matter disease as differential diagnosis of primary progressive multiple sclerosis: A case report. (25135182)
2014
36
Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis. (23756680)
2014
37
Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. (25254339)
2014
38
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. (24909126)
2014
39
A new CSF1R mutation presenting with an extensive white matter lesion mimicking primary progressive multiple sclerosis. (24034409)
2013
40
Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. (24277735)
2013
41
Treatment of primary progressive multiple sclerosis. (23709215)
2013
42
A new model for primary-progressive multiple sclerosis? (24036552)
2013
43
Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. (23818017)
2013
44
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. (23637915)
2013
45
A case of hereditary diffuse leukoencephalopathy with axonal spheroids caused by a de novo mutation in CSF1R masquerading as primary progressive multiple sclerosis. (23698128)
2013
46
Opposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosis. (23840674)
2013
47
Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. (20803344)
2011
48
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis. (21320996)
2011
49
Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. (20463744)
2010
50
Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. (20067515)
2010

Variations for Primary Progressive Multiple Sclerosis

About this section

Expression for genes affiliated with Primary Progressive Multiple Sclerosis

About this section
Search GEO for disease gene expression data for Primary Progressive Multiple Sclerosis.

Pathways for genes affiliated with Primary Progressive Multiple Sclerosis

About this section

Pathways related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 28)
idSuper pathwaysScoreTop Affiliating Genes
19.9IFNB1, TNF
29.9MBP, PLP1
39.6IFNB1, IL10, TNF
4
Show member pathways
9.6IFNB1, IL10, TNF
59.5CSF1R, IFNB1, TNF
69.5IL10, PLP1, TNF
79.4IL10, IL7R, TNF
89.4IL10, IL7R, TNF
99.4CSF1R, IL7R, TNF
109.3TNF, VCAM1
119.3ICAM1, MMP9
129.2ICAM1, IL10, TNF
139.0ICAM1, MMP9, TNF
148.8CSF1R, IFNB1, IL10, IL7R, TNF
158.7ICAM1, TNF, VCAM1
168.7ICAM1, TNF, VCAM1
178.7ICAM1, TNF, VCAM1
188.5ICAM1, MMP9, VCAM1
198.4ICAM1, IL10, TNF, VCAM1
208.4ICAM1, IL10, TNF, VCAM1
218.4ICAM1, IL10, TNF, VCAM1
228.3ICAM1, MBP, MMP9, OMG, TNF
238.2ICAM1, MMP9, TNF, VCAM1
24
Show member pathways
8.2ICAM1, MMP9, TNF, VCAM1
258.2ICAM1, MMP9, TNF, VCAM1
267.8ICAM1, IL10, MMP9, TNF, VCAM1
27
Show member pathways
6.8CSF1R, ICAM1, IFNB1, IL10, IL7R, MMP9
28
Show member pathways
6.3CSF1R, ICAM1, IFNB1, IL10, IL7R, MMP9

GO Terms for genes affiliated with Primary Progressive Multiple Sclerosis

About this section

Cellular components related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:00098979.0ICAM1, IL7R, TNF, VCAM1
2extracellular spaceGO:00056156.6ICAM1, IFNB1, IL10, MMP9, OMG, S100B

Biological processes related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1axon ensheathmentGO:000836610.6MBP, PLP1
2endothelial cell apoptotic processGO:007257710.5IL10, TNF
3negative regulation of heterotypic cell-cell adhesionGO:003411510.5IL10, MBP
4negative regulation of cytokine secretion involved in immune responseGO:000274010.5IL10, TNF
5negative regulation of growth of symbiont in hostGO:004413010.5IL10, TNF
6positive regulation of heterotypic cell-cell adhesionGO:003411610.4IL10, TNF
7osteoclast differentiationGO:003031610.4CSF1R, TNF
8receptor biosynthetic processGO:003280010.4IL10, TNF
9macrophage differentiationGO:003022510.2CSF1R, MMP9
10B cell proliferationGO:004210010.2IFNB1, IL10, IL7R
11positive regulation of leukocyte adhesion to vascular endothelial cellGO:190499610.2ICAM1, TNF
12central nervous system developmentGO:000741710.1MBP, MOG, S100B
13leukocyte tethering or rollingGO:005090110.0TNF, VCAM1
14cellular response to lipopolysaccharideGO:00712229.9ICAM1, IL10, TNF
15positive regulation of vascular smooth muscle cell proliferationGO:19047079.9IL10, MMP9, TNF
16positive regulation of protein phosphorylationGO:00019349.9CSF1R, MMP9, TNF
17inflammatory responseGO:00069549.8CSF1R, IL10, PLP1, TNF
18B cell differentiationGO:00301839.8IFNB1, IL10, VCAM1
19leukocyte cell-cell adhesionGO:00071599.7ICAM1, VCAM1
20membrane to membrane dockingGO:00226149.7ICAM1, VCAM1
21regulation of cell shapeGO:00083609.5CSF1R, ICAM1, S100B
22response to glucocorticoidGO:00513849.3IL10, S100B, TNF
23extracellular matrix organizationGO:00301988.9ICAM1, MMP9, TNF, VCAM1

Molecular functions related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1structural constituent of myelin sheathGO:00199119.9MBP, PLP1

Sources for Primary Progressive Multiple Sclerosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet